Effect of baxdrostat on ambulatory blood pressure in patients with resistant hypertension (Bax24): a phase 3, randomised, double-blind, placebo-controlled trial
Primary result · Change in least-squares mean 24 h ambulatory SBPResult — go to the resultPlacebo-corrected difference −14.0 mm Hg CI −17.2 to −10.8Authors' conclusion
Baxdrostat significantly reduced 24 h ambulatory SBP versus placebo in patients with resistant hypertension
Study context
- Population
- Adults with resistant hypertension (seated systolic blood pressure (SBP) ≥140 and <170 mm Hg despite ≥3 antihypertensives incl. a diuretic; 24 h ambulatory SBP ≥130 mm Hg after placebo run-in)89 vs 95 analysed at 12 wk
- Participants
- 217 adults
- Comparison
- Baxdrostat 2 mg vs placebo
- Baxdrostatn = 108
- Placebon = 109reference
- Primary endpoint
- Change in 24 h ambulatory SBP from baseline
- Follow-up
- Week 12
Methodological detailsphase 3, double-blind, placebo-controlled, international, 79 sites in 22 countries
- Phase 3
- Double-blind
- Placebo-controlled
- International
- 79 sites in 22 countries
Primary result
Change in least-squares mean 24 h ambulatory SBP · 12 weeks
Placebo-corrected difference
−14.0 mm Hg
CI −17.2 to −10.8
P < 0.0001
Change by group
Baxdrostat
−16.6
least-squares mean change · 95% CI −18.8–-14.3 · mm Hg
Placebo
−2.6
least-squares mean change · 95% CI −4.7–-0.4 · mm Hg
Baxdrostat vs Placebo
placebo-corrected difference −14.0 mm Hg (CI −17.2 to −10.8); P < 0.0001
As reported in the abstract
Safety
Adverse events
| Outcome | Baxdrostat | Placebo |
|---|---|---|
| Confirmed potassium >6 mmol/L | 3% | 0 events |
Original publication
Effect of baxdrostat on ambulatory blood pressure in patients with resistant hypertension (Bax24): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. Published 7 March 2026. doi:10.
Summarised from the published abstract; every number is checked against it